伦伐替尼联合 Pembrolizumab 治疗重度预处理转移性胸腺癌:病例报告

IF 0.2 Q4 ONCOLOGY
Angelo Cabal , Misako Nagasaka
{"title":"伦伐替尼联合 Pembrolizumab 治疗重度预处理转移性胸腺癌:病例报告","authors":"Angelo Cabal ,&nbsp;Misako Nagasaka","doi":"10.1016/j.cpccr.2024.100315","DOIUrl":null,"url":null,"abstract":"<div><p>Thymoma and thymic carcinomas are rare tumors with limited therapeutic options for platinum-refractory cases. Recent studies have shown positive response rates in anti-angiogenic multi-kinase inhibitors (MKI) such as lenvatinib and sunitinib and immune checkpoint inhibitors including pembrolizumab, though they have yet to be tested in combination. Here, we present a case of a patient with heavily pre-treated PD-L1 negative metastatic thymic carcinoma and no targetable mutations treated with combination lenvatinib and pembrolizumab following initial response then progression from lenvatinib monotherapy. He had a partial response with decreased tumor burden in the liver with lenvatinib monotherapy and then in the lungs with combination therapy. Treatment was continued and he continues have clinical benefit with stable disease at 9 months with minimal toxicities. This case is one of the first reported clinical evidence for MKI and immunotherapy in combination as a promising second-line approach for thymic carcinomas.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"15 ","pages":"Article 100315"},"PeriodicalIF":0.2000,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000383/pdfft?md5=7d4e4649bddd9dc1a0f480ca54db15cb&pid=1-s2.0-S2666621924000383-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Lenvatinib in combination with pembrolizumab in heavily pretreated metastatic thymic carcinoma: A case report\",\"authors\":\"Angelo Cabal ,&nbsp;Misako Nagasaka\",\"doi\":\"10.1016/j.cpccr.2024.100315\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Thymoma and thymic carcinomas are rare tumors with limited therapeutic options for platinum-refractory cases. Recent studies have shown positive response rates in anti-angiogenic multi-kinase inhibitors (MKI) such as lenvatinib and sunitinib and immune checkpoint inhibitors including pembrolizumab, though they have yet to be tested in combination. Here, we present a case of a patient with heavily pre-treated PD-L1 negative metastatic thymic carcinoma and no targetable mutations treated with combination lenvatinib and pembrolizumab following initial response then progression from lenvatinib monotherapy. He had a partial response with decreased tumor burden in the liver with lenvatinib monotherapy and then in the lungs with combination therapy. Treatment was continued and he continues have clinical benefit with stable disease at 9 months with minimal toxicities. This case is one of the first reported clinical evidence for MKI and immunotherapy in combination as a promising second-line approach for thymic carcinomas.</p></div>\",\"PeriodicalId\":72741,\"journal\":{\"name\":\"Current problems in cancer. Case reports\",\"volume\":\"15 \",\"pages\":\"Article 100315\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2024-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666621924000383/pdfft?md5=7d4e4649bddd9dc1a0f480ca54db15cb&pid=1-s2.0-S2666621924000383-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current problems in cancer. Case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666621924000383\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621924000383","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

胸腺瘤和胸腺癌是罕见肿瘤,对铂类药物难治性病例的治疗方案有限。最近的研究显示,来伐替尼、舒尼替尼等抗血管生成多激酶抑制剂(MKI)和包括pembrolizumab在内的免疫检查点抑制剂的阳性反应率较高,但它们尚未进行联合试验。在此,我们介绍了一例PD-L1阴性且无靶向突变的重度预处理转移性胸腺癌患者的病例,该患者在接受来伐替尼单药治疗后出现初步应答,随后病情进展,随后接受来伐替尼和pembrolizumab联合治疗。来伐替尼单药治疗后,他的肝脏出现部分反应,肿瘤负荷减轻;联合治疗后,肺部肿瘤负荷减轻。他继续接受治疗,并在9个月后病情稳定,毒性极低,继续获得临床获益。该病例是MKI和免疫疗法联合作为胸腺癌二线治疗方法的首批临床证据之一。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Lenvatinib in combination with pembrolizumab in heavily pretreated metastatic thymic carcinoma: A case report

Thymoma and thymic carcinomas are rare tumors with limited therapeutic options for platinum-refractory cases. Recent studies have shown positive response rates in anti-angiogenic multi-kinase inhibitors (MKI) such as lenvatinib and sunitinib and immune checkpoint inhibitors including pembrolizumab, though they have yet to be tested in combination. Here, we present a case of a patient with heavily pre-treated PD-L1 negative metastatic thymic carcinoma and no targetable mutations treated with combination lenvatinib and pembrolizumab following initial response then progression from lenvatinib monotherapy. He had a partial response with decreased tumor burden in the liver with lenvatinib monotherapy and then in the lungs with combination therapy. Treatment was continued and he continues have clinical benefit with stable disease at 9 months with minimal toxicities. This case is one of the first reported clinical evidence for MKI and immunotherapy in combination as a promising second-line approach for thymic carcinomas.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
0
审稿时长
96 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信